Every material Form 8-K KESTRA MEDICAL TECHNOLOGIES, LTD. has filed with the SEC since March 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kestra Medical Technologies reported first quarter fiscal 2027 revenue of $31.0 million, up 60% from the prior year period, and raised its FY27 revenue guidance to $141 million from $137 million. The GAAP net loss widened to $44.1 million from $25.8 million, so revenue growth came with larger losses for shareholders.
Revenue was $31.0 million for the quarter ended July 31, 2026, up 60% from the prior year period; gross margin was 56.5% versus 45.7%.
GAAP net loss was $44.1 million, or $0.75 per share, compared with $25.8 million, or $0.50 per share, a year earlier.
FY27 revenue guidance was increased to $141 million, growth of 48% over FY26, from prior guidance of $137 million.
Cash, cash equivalents and investments totaled $244.7 million as of July 31, 2026; total liquidity was about $320 million including committed unused term loan availability.
Kestra Medical reported fiscal fourth-quarter 2026 revenue of $28.6 million, up 66%, and gave fiscal 2027 revenue guidance of $137 million, 44% above fiscal 2026. On July 10, 2026, it also entered a five-year senior secured term loan facility of up to $200.0 million, with $75.0 million funded at closing and used to repay its prior loan, which matters to shareholders because it adds debt secured by substantially all company assets.
Fiscal 4Q26 revenue was $28.6 million, up 66%, and gross margin was 54.8% versus 44.3% a year earlier.
FY27 revenue guidance is $137 million, compared with FY26 revenue of $95.1 million.
GAAP net loss was $38.8 million for the quarter versus $51.1 million a year earlier, but $131.6 million for the full year versus $113.8 million in FY25.
The July 10, 2026 loan has a $200.0 million facility, matures July 10, 2031, and requires at least $20.0 million in minimum liquidity.
Kestra Medical Technologies reported revenue of $24.6 million for the quarter ended January 31, 2026, up 63% from the prior year, and raised its fiscal 2026 revenue guidance to $93 million from $91 million. The net loss widened to $34.2 million from $21.8 million, so shareholders are weighing faster sales growth against larger losses.
Q3 FY26 revenue was $24.6 million, up 63% from $15.1 million in the prior year period.
Gross margin was 52.6% versus 43.4% a year earlier; gross profit was $12.9 million versus $6.5 million.
GAAP net loss was $34.2 million versus $21.8 million; adjusted EBITDA loss was $21.2 million versus $16.3 million.
FY26 revenue guidance rose to $93 million from $91 million (initial guidance $85 million); cash and cash equivalents were $291 million at January 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every KESTRA MEDICAL TECHNOLOGIES, LTD. filing is on SEC EDGAR ↗. 8-K briefs of other companies →